Indoco Remedies Limited (NSE:INDOCO)
198.36
+0.81 (0.41%)
At close: Mar 6, 2026
Indoco Remedies Revenue
Indoco Remedies had revenue of 4.45B INR in the quarter ending December 31, 2025, with 8.48% growth. This brings the company's revenue in the last twelve months to 17.60B, up 2.06% year-over-year. In the fiscal year ending March 31, 2025, Indoco Remedies had annual revenue of 16.65B, down -8.38%.
Revenue (ttm)
17.60B
Revenue Growth
+2.06%
P/S Ratio
1.04
Revenue / Employee
2.93M
Employees
6,000
Market Cap
18.31B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 16.65B | -1.52B | -8.38% |
| Mar 31, 2024 | 18.17B | 1.49B | 8.91% |
| Mar 31, 2023 | 16.69B | 1.28B | 8.30% |
| Mar 31, 2022 | 15.41B | 2.99B | 24.10% |
| Mar 31, 2021 | 12.42B | 1.35B | 12.19% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innova Captab | 14.97B |
| Solara Active Pharma Sciences | 12.55B |
| Windlas Biotech | 8.68B |
| Orchid Pharma | 8.11B |
| RPG Life Sciences | 6.74B |
| Ind-Swift Laboratories | 5.94B |
| Sigachi Industries | 4.85B |
| Beta Drugs | 3.85B |
Indoco Remedies News
- 12 days ago - Indoco Remedies receives USFDA final approval for Brivaracetam Oral Solution 10 mg/mL - Business Upturn
- 4 weeks ago - Q3 2026 Indoco Remedies Ltd Earnings Call Transcript - GuruFocus
- 4 weeks ago - Indoco Remedies Q3 Results: Revenue rises 8.5% YoY to Rs 445.4 crore, net loss at Rs 29.8 crore - Business Upturn
- 4 months ago - Indoco Remedies Ltd (BOM:532612) Q2 2026 Earnings Call Highlights: Revenue Growth and Strategic ... - GuruFocus
- 4 months ago - Q2 2026 Indoco Remedies Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - Indoco Remedies’ Patalganga API facility clears USFDA inspection with zero observations - Business Upturn
- 7 months ago - Why are Indoco Remedies shares up 2% today? Explained - Business Upturn
- 7 months ago - Indoco Remedies gets USFDA nod for generic Rivaroxaban tablets; eyes growth in US Market - Business Upturn